RT Journal Article
SR Electronic
T1 Age-dependent risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.25.20027672
DO 10.1101/2020.02.25.20027672
A1 Li, Hongdou
A1 Wang, Shuang
A1 Zhong, Fan
A1 Bao, Wuyin
A1 Li, Yipeng
A1 Liu, Lei
A1 Wang, Hongyan
A1 He, Yungang
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.02.25.20027672.abstract
AB New coronavirus SARS-CoV-2 poses a big challenge for global public health in early 2020. Coronavirus Disease 2019 (COVID-19) caused by the virus rapidly spreads all over the world and takes thousands of lives in just two months. It is critical to refine the incidence and mortality risks of COVID-19 for the effective management of the general public and patients in the outbreak. In this report, we investigate the incidence and mortality risks of the infection by analyzing the age composition of 5319 infected patients, 76 fatal cases, and 1,144,648 individuals of the general public in China. Our result shows a relatively low incidence risk for young people but a very high mortality risk for seniors. Notably, mortality risk could be as high as 0.48 for people older than 80 years. Furthermore, our study suggests that a good medical service can effectively reduce the mortality rate of the viral infection to 1% or less.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from National Natural Science Foundation of China (Grant No. 31871255 and 91731310 to Y.H.) and Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is avaliable upon request.